For over 25 years we have been working with outstanding MedTech entrepreneurs to bring medical innovation to patients. The technologies we back improve patient outcomes and save lives.
415 Capital is a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States, and Israel.
We primarily invest in innovative medical device technologies addressing cardiovascular disease: the worldwide leading cause of death and the single largest cost driver in the global healthcare system.
We are investors AND entrepreneurs: As investors, we have funded 44 MedTech companies in the past 28 years. As entrepreneurs, we have founded, built, and exited several successful European MedTech distribution companies.
Target sector: MedTech
Early / pre-commercial
Europe, U.S. and Israel
€5–10 million per company
CVD comprises a variety of health disorders affecting the heart and blood vessels of the human body, including coronary heart disease (e.g. heart-attack), congenital or acquired heart defects (e.g. structural heart disease), heart failure, brain stroke, and aortic & peripheral vascular disease. CVD is the single most costly health condition globally, both in terms of its human toll (quality of life impact and annual deaths) and its global economic impact:
MedTech companies funded